Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease

Cancer Research

Volumn 62, Issue 10, 2002, Pages 2942-2950

  Hellawell, Giles O ^a,d   Turner, Gareth D H ^b   Davies, David R ^b   Poulsom, Richard ^c   Brewster, Simon F ^d   Macaulay, Valentine M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SHC; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CELL ADHESION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEPTOR DOWN REGULATION; TUMOR GROWTH;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DOWN-REGULATION; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0037092971     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Cancer statistics, 1997
2. Peptide growth factors in the prostate as mediators of stromal epithelial interaction
3. Advanced prostate cancer: What's new in hormonal manipulation?
4. The IGF-1 receptor in cancer research
5. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines
6. Insulin-like growth factor-1 increases αVβ3 affinity by increasing the amount of integrin-associated protein that is associated with non raft domains of the cellular membrane
7. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin
8. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells
9. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation
10. Expression of insulin-like growth factor-I receptor in human colorectal cancer
11. Expression of insulin-like growth factor-I receptor (IGF-IR) and p27Kip1 in melanocytic tumors: A potential regulatory role of IGF-I pathway in distribution of p27Kip1 between different cyclins
12. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
13. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
14. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase
15. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
16. Insulin-like growth factor I and prostate cancer risk: A population-based, case-control study
17. Insulin-like growth factors (IGFs). IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
18. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
19. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
20. Insulin-like growth factor receptor expression in prostate cancer
21. Metastatic prostate cancer in a transgenic mouse
22. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
23. The LNCaP cell line - A new model for studies on human prostatic carcinoma
24. The contradictions of the insulin-like growth factor I receptor
25. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect
26. The IGF-I receptor in cell-growth, transformation and apoptosis
27. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
28. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
29. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN
30. Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines
31. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I
32. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells
33. Effect of a null mutation of the insulin-like growthfactor-I receptor gene on growth and transformation of mouse embryo fibroblasts
34. Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections
35. 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway
36. The localization of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: An in situ hybridization and immunocytochemical study
37. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
38. Analysis of foetal expression sites of human type II DNA topoisomerase α and β mRNAs by in situ hybridisation
39. PTEN expression is maintained in sporadic colorectal turnouts
40. The EnVision++ system: A new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques
41. Insulin-like growth factor-I (IGF-I) and insulin-like growth factor receptor (IGF-R1) in prostate cancer
42. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: Correlation with clinico-pathological parameters
43. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
44. Delineation of prognostic biomarkers in prostate cancer
45. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray
46. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array
47. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
48. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulinlike growth factor I with its receptor
49. Expression of insulin-like growth factor-I and its receptor by SV40-transformed rat granulosa cells
50. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent
51. Reexpression of the type-1 insulin-like growth-factor receptor inhibits the malignant phenotype of simian-virus-40 t-antigen immortalized human prostate epithelial -cells
52. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-I in prostate cancer cells
53. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)